Search Results

The CATIE and CUtLASS Studies in Schizophrenia: Results and Implications for Clinicians

Authors: Naber, Dieter; Lambert, Martin

Source: CNS Drugs, Volume 23, Number 8, 8 August 2009 , pp. 649-659(11)

Publisher: Adis International

Molecular characterization of an international cacao collection using microsatellite markers

Authors: Zhang, Dapeng; Mischke, Sue; Johnson, Elizabeth; Phillips-Mora, Wilbert; Meinhardt, Lyndel

Source: Tree Genetics & Genomes, Volume 5, Number 1, January 2009 , pp. 1-10(10)

Publisher: Springer

Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study

Authors: Feng, Yan; Pollock, Bruce G.; Coley, Kim; Marder, Stephen; Miller, Del; Kirshner, Margaret; Aravagiri, Manickam; Schneider, Lon; Bies, Robert R.

Source: British Journal of Clinical Pharmacology, Volume 66, Number 5, November 2008 , pp. 629-639(11)

Publisher: Blackwell Publishing

Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK

Authors: Davies, Andrew; Vardeva, Kawitha; Loze, Jean-Yves; L'Italien, Gilbert J.; Sennfalt, Karin; van Baardewijk, Marc

Source: Current Medical Research and Opinion, Volume 24, Number 11, November 2008 , pp. 3275-3285(11)

Publisher: Informa Healthcare

Aripiprazole: 6-month outcomes in a retrospective naturalistic study

Authors: Deslandes, Paul; Thomas, Arwel; Blackmore, Eve; Sewell, Robert

Source: International Journal of Psychiatry in Clinical Practice, Volume 12, Number 4, 2008 , pp. 243-246(4)

Publisher: Informa Healthcare

Duration of Antipsychotic Drug Therapy in Real-World Practice: A Comparison with CATIE Trial Results

Authors: Chen, Lei; McCombs, Jeffrey S.; Park, Jinhee

Source: Value in Health, Volume 11, Number 3, May/June 2008 , pp. 487-496(10)

Publisher: Blackwell Publishing

Pharmacological Management of Atypical Antipsychotic-Induced Weight Gain

Authors: Baptista, Trino; ElFakih, Yamily; Uzcátegui, Euderruh; Sandia, Ignacio; Tálamo, Eduardo; Enma Araujo de Baptista,; Beaulieu, Serge

Source: CNS Drugs, Volume 22, Number 6, 2008 , pp. 477-495(19)

Publisher: Adis International

The CATIE Schizophrenia Trial: Results, Impact, Controversy

Authors: Manschreck, Theo; Boshes, Roger

Source: Harvard Review of Psychiatry, Volume 15, Number 5, September 2007 , pp. 245-258(14)

Publisher: Informa Healthcare

Reviewing CATIE for clinicians: balancing benefit and risk using evidence-based medicine tools

Authors: Karagianis, Jamie; Rosenbluth, Michael; Tohen, Mauricio; Ascher-Svanum, Haya; Treuer, Tamas; Silva de Lima, Mauricio; Citrome, Leslie

Source: Current Medical Research and Opinion, Volume 23, Number 10, October 2007 , pp. 2551-2557(7)

Publisher: Informa Healthcare

Effektivität atypischer Antipsychotika bei Patienten mit Alzheimer-Demenz: CATIE-AD-Studie (Clinical Antipsychotic Trials of Intervention Effectiveness Alzheimer's Disease)

Author: Förstl, H.

Source: Der Internist, Volume 48, Number 6, June 2007 , pp. 642-644(3)

Publisher: Springer

National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness- Alzheimer's Disease (CATIE-AD): Baseline Characteristics

Authors: M. Saleem Ismail,; Karen Dagerman,; Pierre N. Tariot,; Shana Abbott,; Sarah Kavanagh,; Lon S. Schneider,

Source: Current Alzheimer Research, Volume 4, Number 3, July 2007 , pp. 325-335(11)

Publisher: Bentham Science Publishers

Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial

Authors: Rosenheck, Robert; Swartz, Marvin; McEvoy, Joseph; Stroup, T Scott; Davis, Sonia; Keefe, Richard SE; Hsiao, John; Lieberman, Jeffrey

Source: Expert Review of Pharmacoeconomics and Outcomes Research, Volume 7, Number 2, April 2007 , pp. 103-111(9)

Publisher: Expert Reviews

CATIE'S LESSONS

Author: Royall, Donald R.

Source: Journal of the American Geriatrics Society, Volume 55, Number 4, April 2007 , pp. 636-637(2)

Publisher: Blackwell Publishing

Use of treatment guidelines in clinical decision making in bipolar disorder: a pilot survey of clinicians

Author: Perlis, Roy H.

Source: Current Medical Research and Opinion, Volume 23, Number 3, March 2007 , pp. 467-475(9)

Publisher: Informa Healthcare

The case for long-acting antipsychotic agents in the post-CATIE era

Author: Nasrallah, H. A.

Source: Acta Psychiatrica Scandinavica, Volume 115, Number 4, April 2007 , pp. 260-267(8)

Publisher: Blackwell Publishing

Ethical Principles for Psychiatric Administrators: The Challenge of Formularies

Author: Moffic, H.

Source: Psychiatric Quarterly, Volume 77, Number 4, December 2006 , pp. 319-327(9)

Publisher: Springer

CATIE for clinicians

Author: Kerwin, R.

Source: International Journal of Clinical Practice, Volume 60, Number 8, August 2006 , pp. 892-893(2)

Publisher: Blackwell Publishing

Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians?

Authors: CITROME, L.; STROUP, T. SCOTT

Source: International Journal of Clinical Practice, Volume 60, Number 8, August 2006 , pp. 933-940(8)

Publisher: Blackwell Publishing

Second-line antipsychotics compared in CATIE

Source: Inpharma, Volume 1, Number 1535, 2006-04-29 , pp. 13-13(1)

Publisher: Adis International

Variability in response of seeds to liquid nitrogen exposure in wild coffee (Coffea arabica L.)

Authors: Vasquez, N.; Salazar, K.; Anthony, F.; Chabrillange, N.; Engelmann, F.; Dussert, S.

Source: Seed Science and Technology, Volume 33, Number 2, July 2005 , pp. 293-301(9)

Publisher: International Seed Testing Association